返回
TransThera Sciences (Nanjing), Inc.（02617.HK）價格
02617.HK 股價走勢圖
TRANSTHERA-B (02617.HK)
TransThera Sciences (Nanjing), Inc.
HK$93.1
-2.51%
$-2.4
休市： Jan 19, 16:00:00 HKT
關鍵數據
前收市價
$95.5
開盤價
$95.5
當日範圍
$92.9 - $97.95
52週區間
$20.2 - $679.5
交易量
589.5K
平均成交量
1.7M
每股盈餘 (TTM)
-0.66
股息收益率
--
市值
$28.0B
什麼是 TRANSTHERA-B？
TransThera Sciences (Nanjing), Inc. engages in the research and development of clinical biopharmaceutics. The company is headquartered in Nanjing, Jiangsu and currently employs 121 full-time employees. The company went IPO on 2025-06-23. The firm's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The firm's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). The company is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.
